IHT Wealth Management’s Sonnet BioTherapeutics SONN Stock Holding History

IHT Wealth Management’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4	Closed	-$26K	–	766
2020 Q3	$26K	Buy	+4	New	+$28.8K	﹤0.01%	657

Other funds holding SONN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MSFS

Main Street Financial Solutions Newtown, Pennsylvania $1.34B AUM 19.49% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

IHT Wealth Management's SONN Position: Q4 2020 in Review

IHT Wealth Management sold out of Sonnet BioTherapeutics (SONN) in Q4 2020, closing a stake of 4 shares — an estimated $26K sold.

IHT Wealth Management first reported a position in SONN in Q3 2020 and held it in 1 quarter. The position peaked at $26K in Q3 2020. 8 funds tracked by Wall St. Rank hold SONN as of Q4 2020.

IHT Wealth Management reported no remaining Sonnet BioTherapeutics position as of Q4 2020 after selling out during the quarter.
IHT Wealth Management sold 4 Sonnet BioTherapeutics shares in Q4 2020, an estimated $26K.
IHT Wealth Management first reported a position in Sonnet BioTherapeutics in Q3 2020 and held it in 1 quarter.
IHT Wealth Management's Sonnet BioTherapeutics position peaked at $26K in Q3 2020.
8 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2020.

Based on IHT Wealth Management's 13F filing for Q4 2020, filed 17 Feb 2021.